A preliminary study on the diagnostic performance of the uPath PD-L1 (SP263) artificial intelligence (AI) algorithm in patients with NSCLC treated with PD-1/PD-L1 checkpoint blockade.

Journal: Pathologica
PMID:

Abstract

OBJECTIVE: The uPath PD-L1 (SP263) is an AI-based platform designed to aid pathologists in identifying and quantifying PD-L1 positive tumor cells in non-small cell lung cancer (NSCLC) samples stained with the SP263 assay.

Authors

  • Alessio Cortellini
    Operative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, Rome, Italy.
  • Claudia Zampacorta
    Center for Advanced Studies and Technology (CAST), University Chieti-Pescara, Italy.
  • Michele De Tursi
    Department of Innovative Technologies in Medicine & Dentistry, University G. D'Annunzio, Chieti-Pescara, Italy.
  • Lucia R Grillo
    Anatomic Pathology Unit, San Camillo-Forlanini Hospitals, Rome, Italy.
  • Serena Ricciardi
    Medical Oncology, San Camillo Forlanini Hospital, Roma, Italy.
  • Emilio Bria
    Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Maurizio Martini
    Gaetano Barresi Department of Human and Paediatric Pathology, Pathology Section, University of Messina, Messina, Italy.
  • Raffaele Giusti
    Medical Oncology Unit, Azienda Ospedaliero Universitaria Sant'Andrea, Rome, Italy.
  • Marco Filetti
    Uoc Fase 1, Fondazione Policlinico universitario Agostino Gemelli, Irccs, Roma - Dipartimento di Medicina sperimentale, Sapienza Università di Roma - Ph.D. Program in "Network oncology and precision medicine", Sapienza Università di Roma.
  • Antonella Dal Mas
    Pathology Unit, St. Salvatore Hospital, L'Aquila, Italy.
  • Marco Russano
    Operative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, Rome, Italy; Department of Surgery and Cancer, Hammersmith Hospital Campus, Imperial College London, London, United Kingdom.
  • Filippo Gustavo Dall'Olio
    Departement de Medicine Oncologique, Institut Gustave Roussy, Villejuif, France.
  • Fiamma Buttitta
    Center for Advanced Studies and Technology (CAST), University Chieti-Pescara, Italy.
  • Antonio Marchetti
    Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.